301 related articles for article (PubMed ID: 12869353)
1. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression.
Steiner S; Seidinger D; Huber K; Kaun C; Minar E; Kopp CW
Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1697-702. PubMed ID: 12869353
[TBL] [Abstract][Full Text] [Related]
2. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
3. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
4. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
Straub A; Wendel HP; Azevedo R; Ziemer G
Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
[TBL] [Abstract][Full Text] [Related]
5. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting.
Kopp CW; Steiner S; Nasel C; Seidinger D; Mlekusch I; Lang W; Bartok A; Ahmadi R; Minar E
Stroke; 2003 Nov; 34(11):2560-7. PubMed ID: 14563968
[TBL] [Abstract][Full Text] [Related]
6. Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab.
Ray MJ; Walters DL; Bett JN; Cameron J; Wood P; Aroney CN
Int J Cardiol; 2005 May; 101(2):249-55. PubMed ID: 15882672
[TBL] [Abstract][Full Text] [Related]
7. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia.
Mak KH; Kottke-Marchant K; Brooks LM; Topol EJ
Thromb Haemost; 1998 Dec; 80(6):989-93. PubMed ID: 9869172
[TBL] [Abstract][Full Text] [Related]
8. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro.
Scholz T; Zhao L; Temmler U; Bath P; Heptinstall S; Lösche W
Platelets; 2002 Nov; 13(7):401-6. PubMed ID: 12487787
[TBL] [Abstract][Full Text] [Related]
9. P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist.
Zhao L; Bath PM; May J; Lösche W; Heptinstall S
Platelets; 2003; 14(7-8):473-80. PubMed ID: 14713516
[TBL] [Abstract][Full Text] [Related]
10. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
Matzdorff A; Voss R
Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
[TBL] [Abstract][Full Text] [Related]
12. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Marciniak SJ; Mascelli MA; Furman MI; Michelson AD; Jakubowski JA; Jordan RE; Marchese PJ; Frelinger AL
Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
[TBL] [Abstract][Full Text] [Related]
14. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
15. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction.
Neumann FJ; Zohlnhöfer D; Fakhoury L; Ott I; Gawaz M; Schömig A
J Am Coll Cardiol; 1999 Nov; 34(5):1420-6. PubMed ID: 10551687
[TBL] [Abstract][Full Text] [Related]
16. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
Mousa SA; Khurana S; Forsythe MS
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
[TBL] [Abstract][Full Text] [Related]
18. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
[TBL] [Abstract][Full Text] [Related]
19. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Schneider DJ; Taatjes DJ; Sobel BE
Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
